|
T12893 |
SGLT inhibitor-1
|
|
SGLT
|
|
SGLT inhibitor-1 is a potentsodium glucose co-transporter proteins (SGLTs) dual inhibitor(hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively). |
|
T9590 |
T-1095
|
|
SGLT
,
transporter
|
|
T-1095 is an inhibitor of renal glucose reabsorption and the expression of Na+-glucose cotransporters (SGLTs) and facilitative glucose transporter 2 (GLUT2). |
|
T2385 |
Ipragliflozin
|
ASP1941 |
SGLT
|
|
Ipragliflozin (ASP1941) is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2. |
|
T15656 |
KGA-2727
|
|
SGLT
|
|
KGA-2727 is a potent and selective SGLT1 inhibitor, with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA... |
|
T1766 |
Empagliflozin
|
BI 10773 |
SGLT
|
|
Empagliflozin (BI 10773) is an SGLT-2 inhibitor (IC50=3.1 nM) that is potent and selective, with more than 300-fold selectivity for SGLT-1/4/5/6. Empagliflozin is used for the treatment of type 2 diabetes. |
|
T2389 |
Dapagliflozin
|
BMS-512148 |
SGLT
,
HIF
|
|
Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. |
|
T38843 |
Enavogliflozin
|
DWP-16001 |
SGLT
|
|
Enavogliflozin (DWP-16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. |
|
T3547 |
Sotagliflozin
|
LX-4211,LP-802034 |
SGLT
|
|
Sotagliflozin (LP-802034) is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity. |
|
T4999 |
Ertugliflozin
|
MK-8835,PF-04971729 |
SGLT
|
|
PF-04971729 (Ertugliflozin (PF-04971729)) is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2). |
|
T15244 |
Ertugliflozin L-pyroglutamic acid
|
PF-04971729 L-pyroglutamic acid |
Others
,
SGLT
|
|
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a selective and orally active hSGLT2 inhibitor with an IC50 of 0.877 nM. Ertugliflozin L-pyroglutamic acid can be used for studies about the treatmen... |
|
T5016 |
Tofogliflozin (hydrate)
|
Tofogliflozin hydrate,CSG-452 hydrate |
SGLT
,
Reactive Oxygen Species
,
ROS
|
|
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific inhibitor of SGLT2(IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2). |
|
T1782 |
Canagliflozin
|
JNJ 24831754ZAE,JNJ 28431754AAA,TA 7284,JNJ 28431754 |
SGLT
|
|
Canagliflozin (JNJ 28431754AAA), a sodium-glucose transporter 2( SGLT2) and P-Glycoprotein inhibitor, is used in type 2 diabetes. |
|
T39966 |
SGLT1/2-IN-2
|
SGLT1/2-IN-2 |
|
|
SGLT1/2-IN-2 is a chemical compound with robust dual inhibitory properties, exhibiting potent activities against SGLT1 (IC50 = 96 nM) and SGLT2 (IC50 = 1.3 nM). |
|
T4460 |
Dapagliflozin ((2S)-1,2-propanediol, hydrate)
|
BMS-512148 (2S)-1,2-propanediol, hydrate,Dapagliflozin propanediol monohydrate |
SGLT
|
|
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (BMS-512148 (2S)-1,2-propanediol, hydrate) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). It is in development for the tre... |
|
T15752 |
Licogliflozin
|
LIK066 |
SGLT
|
|
Licogliflozin (LIK066) is an inhibitor of sodium-glucose cotransporter (SGLT1 and SGLT2). |
|
T16083 |
Mizagliflozin
|
GSK-1614235 free base,KGA-3235 free base,DSP-3235 free base |
SGLT
|
|
Mizagliflozin (GSK-1614235 free base) is a sodium-glucose transporter inhibitor( Ki of 27 nM for human SGLT1). Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic drug that ca... |
|
T62830 |
SGLT1/2-IN-1
|
|
|
|
SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor. |
|
T28757 |
Sergliflozin etabonate
|
GW-869682,GW-869682X,KGT-1251,GW869682X,GW869682,KGT1251 |
SGLT
|
|
Sergliflozin etabonate (KGT-1251) is an inhibitor of SGLT2 and can be used in studies about type 2 diabetes and obesity. |
|
T28971 |
Tianagliflozin
|
|
|
|
Tianagliflozin, a sodium/glucose cotransporter 2 (SGLT-2) inhibitor, is used potentially for the treatment of type 2 diabetes. |
|
T29188 |
YM-543 trimethylamine
|
ASP 543,ASP-543,ASP543 |
|
|
YM-543, a sodium-glucose transporter 2 (SGLT-2) inhibitor, is used potentially for the treatment of type 2 diabetes. |
|
T68922 |
YM543 free base
|
|
|
|
YM543 free base, a potent and orally active sodium-glucose cotransporter (SGLT) 2 inhibitor, effectively reduces blood glucose levels and is suitable for diabetes research. |
|
T35619 |
Dapagliflozin-3-O-β-D-Glucuronide
|
|
|
|
Dapagliflozin-3-O-β-D-glucuronide is a metabolite of dapagliflozin . Dapagliflozin is a first generation selective sodium glucose cotransporter (SGLT) 2 inhibitor that blocks glucose transport.[1] Dapagliflozin is metab... |
|
TMIH-0013 |
(S)-Empagliflozin-d4
|
|
|
|
(S)-Empagliflozin-d4 is a deuterated compound of (S)-Empagliflozin. (S)-Empagliflozin has a CAS number of 864070-44-0. Empagliflozin is a Sodium-Glucose Cotransporter 2 Inhibitor. The mechanism of action of empagliflozin... |
